| Literature DB >> 30425830 |
S Wilkins1,2, R Yap1, K Loon1, M Staples3, K Oliva1, B Ruggiero1, P McMurrick1, P Carne1,4.
Abstract
BACKGROUND: Abdominoperineal resection (APR) is associated with a poorer oncological outcome than anterior resection. This may be due to higher rates of intra-operative perforation and circumferential resection margin involvement. The aim of this study was to audit our short and long-term results of abdominoperineal resection performed using conventional techniques and to compare this with other published series.Entities:
Keywords: Abdominoperineal; Colorectal; Outcomes; Surgery
Year: 2018 PMID: 30425830 PMCID: PMC6224354 DOI: 10.1016/j.amsu.2018.10.029
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Patient demographics and clinicopathologic characteristics.
| APR n = 163 | % | |
|---|---|---|
| Age | ||
| Median (years, range) | 70 (41–95) | |
| Gender | ||
| Male | 105 | 64.4 |
| Female | 58 | 35.6 |
| AJCC Preoperative stage | ||
| I | 41 | 25.2 |
| II | 55 | 33.7 |
| III | 47 | 28.9 |
| IV | 13 | 8.0 |
| Unknown | 7 | 4.3 |
| Neoadjuvant therapy | ||
| SCRT | 8 | 4.9 |
| LCCRT | 75 | 46.0 |
| None | 79 | 48.5 |
| Other | 1 | 0.6 |
| Surgical Entry | ||
| Open | 135 | 82.8 |
| Conversion | 5 | 3.1 |
| Laparoscopic | 8 | 4.9 |
| Robotic | 10 | 6.1 |
| Hybrid | 5 | 3.1 |
| AJCC Pathological Stage | ||
| 0 | 18 | 11.0 |
| I | 43 | 26.4 |
| II | 45 | 27.6 |
| III | 33 | 20.3 |
| IV | 15 | 9.2 |
| Lymphovascular Invasion | ||
| Yes | 123 | 75.5 |
| No | 40 | 24.5 |
| Differentiation | ||
| Well | 5 | 3.1 |
| Moderate | 115 | 70.5 |
| Poor | 21 | 12.9 |
| No residual | 21 | 12.9 |
| Unknown | 1 | 0.6 |
| Adjacent structures resected | 24 | 14.7 |
| Positive CRM | 6 | 3.7 |
AJCC, American Joint Committee on Cancer; APR, abdominoperineal resection; CRM, circumferential radial margin; LCCRT, long course chemoradiotherapy; SCRT, short course radiotherapy.
Fig. 1Change in surgical technique over time.
Fig. 2Long term outcomes: Disease-free survival by pathological stage.
Multivariate analysis of the factors affecting disease-free survival.
| Variable | HR | SE | P | 95% CI | |
|---|---|---|---|---|---|
| pAJCC | |||||
| 0 | Reference group | ||||
| 1 | 0.535 | 0.662 | 0.613 | 0.048 | 6.034 |
| 2 | 2.078 | 2.230 | 0.496 | 0.254 | 17.030 |
| 3 | 5.522 | 5.739 | 0.100 | 0.720 | 42.336 |
| 4 | 11.035 | 11.539 | 0.022 | 1.422 | 85.666 |
| CRM + status | 3.163 | 1.783 | 0.041 | 1.048 | 9.549 |
| LVI | 3.764 | 1.330 | <0.001 | 1.882 | 7.524 |
| LN yield | 0.920 | 0.030 | 0.011 | 0.863 | 0.981 |
CI, confidence interval; CRM, circumferential radial margin; HR, hazard ratio; LN, lymph node; LVI, lymphovascular invasion; pAJCC, pathological stage according to American Joint Committee on Cancer; SE, standard error.
Fig. 3Long term outcomes: Overall survival by pathological stage.
Age adjusted multi-variate analysis of factors affecting overall survival.
| Variable | HR | SE | P | 95% CI | |
|---|---|---|---|---|---|
| Age | 1.052 | 0.016 | 0.001 | 1.020 | 1.084 |
| pAJCC | |||||
| 0 | Reference group | ||||
| 1 | 0.494 | 0.355 | 0.327 | 0.120 | 2.025 |
| 2 | 0.827 | 0.551 | 0.776 | 0.224 | 3.055 |
| 3 | 1.510 | 0.962 | 0.517 | 0.434 | 5.262 |
| 4 | 4.280 | 2.855 | 0.029 | 1.158 | 15.819 |
| Age | 1.044 | 0.015 | 0.003 | 1.015 | 1.073 |
| pAJCC | 1.728 | 0.264 | <0.001 | 1.281 | 2.331 |
| Age | 1.040 | 0.014 | 0.004 | 1.013 | 1.069 |
| LVI | 1.990 | 0.659 | 0.038 | 1.040 | 3.809 |
CI, confidence interval; HR, hazard ratio; LVI, lymphovascular invasion; pAJCC, pathological stage according to American Joint Committee on Cancer; SE, standard error.
Observed circumferential positive margin rates in patients undergoing std. APR.
| Study | Years | Patients (n) | CRM + |
|---|---|---|---|
| This study | 2000–2015 | 163 | 3.7% |
| Prytz et al., 2014 [ | 2007–2009 | 207 | 6.3% |
| Klein et al., 2015 [ | 2009–2012 | 251 | 7.2% |
| den Dulk et al., 2009 [ | 1987–2002 | 897 | 10.6% |
| Ortiz et al., 2014 [ | 2008–2013 | 457 | 13.1% |
| Kennelly et al., 2013 [ | 1990–2011 | 327 | 13.9% |
| Messenger et al., 2011 | 1997–2006 | 115 | 15.7% |
| Ortiz et al., 2014 [ | 2006–2010 | 920 | 18.1% |
| Asplund et al., 2012 | 2004–2009 | 75 | 20.0% |
| West et al., 2010 | 1997–2008 | 124 | 49.6% |
*Stages 1–3.
Single centre study. Studies with more than 50 patients.